Voyager Therapeutics, Inc. VYGR
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a CNS/neurology/psychiatry drug developer. Its lead program, VY1706, is in Phase 1 for Alzheimer's disease (early stage with tau pathology). Its next catalyst on record is VY7523: VY7523 tau PET imaging efficacy data from MAD trial expected in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VY7523 — VY7523 tau PET imaging efficacy data from MAD trial expected in Q4 2026. (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VY1706 | Alzheimer's disease | gene therapy | Phase 1 |
| VY7523 | Alzheimer's disease | antibody | Phase 1 |
| FA Program (out-licensed to Neurocrine) | Friedreich's ataxia | gene therapy | Phase 1 |
| GBA1 Program (out-licensed to Neurocrine) | Parkinson's disease | gene therapy | Pre-clinical |
| Huntington's disease Program (out-licensed to Novartis) | Huntington's disease | gene therapy | Pre-clinical |
| TDP-43 small molecules (partnered with Transition Bio) | ALS and frontotemporal dementia | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.